These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 15653419

  • 1. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
    Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M.
    J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
    [Abstract] [Full Text] [Related]

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 3. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
    Lo CM, Liu CL, Chan SC, Lau GK, Fan ST.
    J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
    [Abstract] [Full Text] [Related]

  • 9. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V.
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.
    J Gastroenterol; 2002 Nov; 37(11):922-7. PubMed ID: 12483247
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
    Gotto J, Webster GJ, Brown D, Jenkins J, Dusheiko GM, Bertoletti A.
    J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
    [Abstract] [Full Text] [Related]

  • 14. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, Touloumi G, Economou M, Vlachogiannakos J, Spandidos D, Avgerinos A, Tzourmakliotis D.
    Aliment Pharmacol Ther; 2006 Mar 15; 23(6):787-95. PubMed ID: 16556181
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS.
    Hepatology; 2000 Oct 15; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [Abstract] [Full Text] [Related]

  • 18. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
    Gastroenterology; 2007 Nov 15; 133(5):1437-44. PubMed ID: 17983800
    [Abstract] [Full Text] [Related]

  • 19. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH.
    Antivir Ther; 2009 Nov 15; 14(2):203-10. PubMed ID: 19430095
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C, Therapeutic HBV Vaccine Group of Investigators.
    Vaccine; 2007 Dec 12; 25(51):8585-97. PubMed ID: 18031872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.